Responses of young energy-restricted sheep to chronically administered insulin-like growth factor I (IGF-I): evidence that IGF-I suppresses the hepatic growth hormone receptor.

We have shown previously that chronic administration (8 weeks) of insulin-like growth factor-I (IGF-I) has little growth-promoting effect in well fed sheep. The aim of this study was to investigate the anabolic effects of IGF-I in energy-restricted conditions in which circulating concentrations of IGF-I in control animals were expected to be low. Young castrate male sheep were offered chaffed lucerne at a rate equivalent to 110% maintenance and were treated by sc injection three times per day for either 8 or 12 weeks with recombinant human IGF-I (150 micrograms/kg live wt x day) or saline in a 2 x 2 factorial design (eight animals per cell). IGF-I treatment significantly increased plasma IGF-I concentrations, but reduced plasma concentrations of IGF-II, GH, urea, and creatinine. Treatment with IGF-I also decreased (P < 0.1) GH secretion in response to a GRF load, but significantly (P < 0.05) increased the nonesterified fatty acid response to an epinephrine load. The reduction in circulating GH levels was accompanied by a suppression of [125I]oGH binding to hepatic microsomal membranes. This effect, if apparent in other tissues, may act as a feedback mechanism to limit the local synthesis of IGF-I and could explain why IGF-I treatment had little effect on the growth rate of the sheep, although it did increase nitrogen digestibility of the feed consumed and decreased the fat content of the hind leg. It also differentially promoted the growth of the spleen, thymus, and mandibular salivary gland and increased blood counts of eosinophils. It is concluded that IGF-I does not have marked effects on growth rate or body composition in sheep fed a near-maintenance diet. Possible reasons include the associated suppression of GH secretion and action, which limits the ability of treated animals to repartition absorbed nutrients.

Effects of oral IGF-I or IGF-II on digestive organ growth in newborn piglets.

To study whether colostrum-borne growth factors are responsible for the rapid GI tissue growth in naturally suckled newborn animals, newborn unsuckled piglets were bottle-fed for 24 h with infant milk formula with or without addition of 2 micrograms/ml of recombinant human insulin-like growth factor-I (IGF-I) or insulin-like growth factor-II (IGF-II), a level which approximated that of porcine colostrum. The animals were then sacrificed for measurements of their digestive organ weights and contents of protein, RNA and DNA in the organs. The treatment with IGF-I or IGF-II failed to show any significant effect on the weight of the esophagus, stomach, small intestine, large intestine, mandibular glands, kidneys and the spleen, and had no effects on the contents of protein, RNA and DNA in the small intestinal mucosa, the liver and the spleen. However, piglets fed with infant formula containing IGF-I (n = 7) or IGF-II (n = 7) had a heavier pancreas (p < 0.05) compared to formula-fed controls (n = 7). The DNA content in the stomach and the pancreas were greater in animals treated with IGF-I or IGF-II than in controls. Using a cell labelling technique it was shown that both IGF-I and IGF-II stimulated cell proliferation in the small intestinal crypts. The results indicate that the substantial GI tissue growth reported in newborn animals is unlikely due to colostrum-borne IGF-I or IGF-II alone. On the other hand the study does suggest that oral IGF-I and IGF-II are capable of stimulating cell proliferation in the GI tract.